Celularity secures Sharpe Ratio (or Efficiency) of -0.16, which signifies that the company had -0.16% of return per unit of risk over the last 3 months. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Celularity exposes twenty-one different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to confirm Celularity
risk adjusted performance of
(0.16), and Mean Deviation of 2.89 to double-check the risk estimate we provide.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Celularity income statement, its balance sheet, and the statement of cash flows. Potential Celularity investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Celularity investors may use each financial statement separately, they are all related. The changes in Celularity's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Celularity's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Celularity
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Celularity performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Celularity shares is the value that is considered the true value of the share. If
the intrinsic value of Celularity is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Celularity. Please read more on our
fundamental analysis page.
How effective is Celularity in utilizing its assets?
Celularity reports assets on its Balance Sheet. It represents the amount of Celularity resources that either has an existing economic value or will provide some form of benefits in the future. By effectively utilizing its assets, Celularity aims to generate revenue, control costs, drive operational efficiency, and enhance profitability. Optimizing asset utilization helps maximize shareholder value and maintain a competitive position in the Biotechnology space. To get a better handle on how balance sheet or income statements item affect Celularity volatility, please check the breakdown of all its
fundamentals.
Are Celularity Earnings Expected to grow?
The
future earnings power of Celularity involves the interaction of many company-specific, industry, and economic forces. Earnings estimates embody investors' opinions of Celularity factors such as sales growth, product demand, competitive industry environment, profit margins, and cost controls. Celularity
stock prices adjust as these expectations change or are proven wrong. The main thing to remember is that equities with high expected earnings growth tend to underperform the market because it is usually difficult to meet the market's high expectations. Companies with low earnings expectations tend to do better than expected. Please use our latest analysis of Celularity
expected earnings.
Celularity Gross Profit
Celularity Gross Profit growth is one of the most critical measures in evaluating the company. The Gross Profit growth rate is calculated simply by comparing Celularity previous period's values with its current period's values. Each time period you're measuring should be of equal lengths the increase or decrease, in a company's Gross Profit between two periods. Here we show Celularity Gross Profit growth over the last 10 years. Please check Celularity's
gross profit and other
fundamental indicators for more details.
An Additional Perspective On Celularity
Although in the United States, the Securities and Exchange Commission has enforced strong rules to prevent insiders from engaging in insider trading, finding insiders among active shareholders of Celularity is not uncomon. There are few distinct groups of Celularity stakehholders that the SEC considers insiders. Investors usually gain information through their work as corporate directors, officers, or employees. If these individuals share the information with a friend, family, or business partner and the person who receives the information exchanges stock in the company, he or shie is also an insider. Let's take a look at how the ownership of Celularity is distributed among investors.
Ownership Allocation
Celularity holds a total of one hundred twenty-three million four hundred sixty thousand
outstanding shares. Celularity shows majority of its outstanding shares owned by
insiders. An
insider is usually defined as a corporate executive, director, member of the board or
institutional investor who own at least 10% of the company outstanding shares. 73.2 percent of Celularity
outstanding shares that are owned by
insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how much assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
| Retail Investors18.57% | Insiders73.2% | Institutions8.23% |
| Retail Investors | 18.57 |
| Insiders | 73.2 |
| Institutions | 8.23 |
Asset Utilization
One of the ways to look at asset utilization of Celularity is to check how much profit was generated for every dollar of assets it reports. Celularity shows a negative utilization of assets of -17.12 percent, losing $0.17 for each dollar of assets held by the firm. Inadequate asset utilization signifies that the company is being less effective with each dollar of assets it shows. Put another way, asset utilization of Celularity shows how discouraging it operates for each dollar spent on its assets.
| Assets Non Current347.6 M | Goodwill254.1 M |
| Current Assets | 75.22 Million | 11.11 |
| Assets Non Current | 347.57 Million | 51.35 |
| Goodwill | 254.05 Million | 37.54 |
Will Celularity newest gain continue?
Newest information ratio is at -0.19. Celularity exhibits very low volatility with skewness of 0.08 and kurtosis of 0.3. However, we advise investors to further study Celularity technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Celularity's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Celularity's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Celularity Implied Volatility
Celularity's implied volatility exposes the market's sentiment of Celularity stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Celularity's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Celularity stock will not fluctuate a lot when Celularity's options are near their expiration.
Our Conclusion on Celularity
Whereas some other firms under the biotechnology industry are still a bit expensive, Celularity may offer a potential longer-term growth to private investors. With a relatively neutral outlook on the newest economy, it is better to hold off any trading of Celularity as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Celularity.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Gabriel Shpitalnik is a Member of Macroaxis Editorial Board. Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Gabriel Shpitalnik do not own shares of Celularity. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com